Yahoo NewsThe US Government Hopes $190 Million Will Make Gene Editing …GizmodoThe first U.S. trial using CRISPR to treat disease in people is imminent, a significant step in testing the true power of gene editing in the clinic. In the future, the … Continue reading
Viral gene therapy could improve results from breast reconstruction after cancer treatmentMedical XpressThe protection given by the new gene therapy could prevent radiotherapy side-effects in women who have had breast reconstruction surgery, and spare … Continue reading
Market Realist |
How Juno Therapeutics’ Cellular Immunotherapy Portfolio Could Help Celgene
Market Realist (To know more on Novartis’ Kymriah, please refer to Market Realist’s “How Is Novartis’s Kymriah Positioned for 2018?“) In October 2017, the FDA approved Gilead Sciences’ Yescarta for the treatment of certain types of non-Hodgkin lymphoma. The … Here’s Why Fate Therapeutics Rose as Much as 18% TodayMadison.com Juno Therapeutics (JUNO) Lowered to Sell at Zacks Investment ResearchThe Ledger Gazette Celgene’s $9B Buyout of Juno to Boost Company’s Immuno-Oncology PortfolioImmuno-Oncology News Brinkwire (press release) all 89 news articles » |
USC News |
Stem cells used to build bone and fight cancer | USC News
USC News histology of neuroblastoma cells Abigail Zamora will study the cells that cause neuroblastoma, an aggressive cancer that often affects children. (Photo/ Ed Uthman). This year’s Broad Clinical Research Fellows will apply stem cell-based approaches to … |
|
Targeting bladder cancer’s Achilles heel: Stem cells
Science Daily Recent research suggests that this resistance is caused by a small pool of cancer stem cells (CSCs) within these tumors that isn’t killed with chemotherapies, leading tumors to regrow and spread even after initial treatment success. Although … |
Parkinson’s News Today |
Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Advanced Parkinson’s Disease
Parkinson’s News Today Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson’s disease. The trial follows approval by the U.S. Food and Drug Administration of the company … MRI Interventions Recognizes FDA Clearance of Voyager’s Investigational New Drug Application for VY-AADC …GlobeNewswire (press release) |